Drug
dose 3
dose 3 is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
3
75%
Ph not_applicable
1
25%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
N/ANon-phased studies
1(25.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(3)
Completed(1)
Detailed Status
Enrolling by invitation1
Recruiting1
Active, not recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 13 (75.0%)
N/A1 (25.0%)
Trials by Status
enrolling_by_invitation125%
recruiting125%
active_not_recruiting125%
completed125%
Recent Activity
2 active trials
Showing 4 of 4
enrolling_by_invitationphase_1
Safety, Tolerability and Pharmacokinetics of ETD-001 Gel
NCT07674862
recruitingnot_applicable
Reach Through Equitable Implementation in Utah
NCT06881069
active_not_recruitingphase_1
Transfer of Genetically Engineered Lymphocytes in Melanoma Patients
NCT01586403
completedphase_1
Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.)
NCT02088203
Clinical Trials (4)
Showing 4 of 4 trials
NCT07674862Phase 1
Safety, Tolerability and Pharmacokinetics of ETD-001 Gel
NCT06881069Not Applicable
Reach Through Equitable Implementation in Utah
NCT01586403Phase 1
Transfer of Genetically Engineered Lymphocytes in Melanoma Patients
NCT02088203Phase 1
Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.)
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4